董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ronan O'Caoimh | 男 | Chairman and Chief Executive Officer | 64 | 11.90万美元 | 未持股 | 2020-06-15 |
| Jim Walsh | 男 | Executive Director | 61 | 24.00万美元 | 未持股 | 2020-06-15 |
| Denis R. Burger | 男 | Non Executive Director, Lead Director | 76 | 10.00万美元 | 未持股 | 2020-06-15 |
| Clint Severson | 男 | Non Executive Director | 71 | 7.50万美元 | 未持股 | 2020-06-15 |
| James D. Merselis | 男 | Non Executive Director | 66 | 3.80万美元 | 未持股 | 2020-06-15 |
| Kevin Tansley | 男 | Executive Director, Chief Financial Officer & Company Secretary | 49 | 9.10万美元 | 未持股 | 2020-06-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ronan O'Caoimh | 男 | Chairman and Chief Executive Officer | 64 | 11.90万美元 | 未持股 | 2020-06-15 |
| Kevin Tansley | 男 | Executive Director, Chief Financial Officer & Company Secretary | 49 | 9.10万美元 | 未持股 | 2020-06-15 |
董事简历
中英对照 | 中文 | 英文- Ronan O'Caoimh
-
Ronan O'Caoimh，董事长、首席执行官；在1992年6月参与创办Trinity Biotech，并担任首席财务官，直到1994年3月，他成为首席执行官。1995年5月，他还当选为董事长。2007年11月，本公司首席执行官和董事长的职务分离，他于是担任执行董事长。2008年10月，公司首席执行官辞职，他重新担任首席执行官、董事长。加入Trinity Biotech之前，他是爱尔兰诊断公司Noctech Limited的总经理；1988年起，担任其财务总监，直到至1991年1月成为总经理。他在University College Dublin获得商业学士学位，是爱尔兰Institute of Chartered Accountants的资深会员。2011年3月30日，他担任本公司首席执行官的服务协议终止，取而代之的是与Darnick Limited的服务协议。
Ronan O'Caoimh, Chairman and Chief Executive Officer, co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. In November 2007 it was decided to separate the role of Chief Executive Officer and Chairman and Mr O'Caoimh assumed the role of Executive Chairman. In October 2008 following the resignation of the Chief Executive Officer, Mr. O'Caoimh resumed the role of Chief Executive Officer and Chairman. Prior to joining Trinity Biotech, Mr O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O'Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O'Caoimh holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. On March 30 2011 the service agreement with Ronan O'Caoimh as Chief Executive Officer was terminated and replaced by an agreement with Darnick Limited. - Ronan O'Caoimh，董事长、首席执行官；在1992年6月参与创办Trinity Biotech，并担任首席财务官，直到1994年3月，他成为首席执行官。1995年5月，他还当选为董事长。2007年11月，本公司首席执行官和董事长的职务分离，他于是担任执行董事长。2008年10月，公司首席执行官辞职，他重新担任首席执行官、董事长。加入Trinity Biotech之前，他是爱尔兰诊断公司Noctech Limited的总经理；1988年起，担任其财务总监，直到至1991年1月成为总经理。他在University College Dublin获得商业学士学位，是爱尔兰Institute of Chartered Accountants的资深会员。2011年3月30日，他担任本公司首席执行官的服务协议终止，取而代之的是与Darnick Limited的服务协议。
- Ronan O'Caoimh, Chairman and Chief Executive Officer, co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. In November 2007 it was decided to separate the role of Chief Executive Officer and Chairman and Mr O'Caoimh assumed the role of Executive Chairman. In October 2008 following the resignation of the Chief Executive Officer, Mr. O'Caoimh resumed the role of Chief Executive Officer and Chairman. Prior to joining Trinity Biotech, Mr O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O'Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O'Caoimh holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. On March 30 2011 the service agreement with Ronan O'Caoimh as Chief Executive Officer was terminated and replaced by an agreement with Darnick Limited.
- Jim Walsh
-
Jim Walsh，1995年10月第一次加入Trinity Biotech ，担任首席运营官。2007年，他辞去该职，成为本公司的非执行董事。2010年10月，他再次加入本公司，担任首席科学官。加入Trinity Biotech 之前，他是Cambridge Diagnostics Ireland Limited CDIL的总经理；他从1987年起任职于CDIL。加入CDIL之前，他是Fleming GmbH的研发经理。他在University College Galway获得化学博士学位。
Jim Walsh initially joined Trinity Biotech in October 1995 as Chief Operations Officer. Dr Walsh resigned from the role of Chief Operations Officer in 2007 to become a Non Executive Director of the Company. In October, 2010 Dr Walsh rejoined the company as Chief Scientific Officer. Dr Walsh transferred from this position in 2015 and focuses on Business Development activities. Prior to joining Trinity Biotech, Dr Walsh was Managing Director of Cambridge Diagnostics Ireland Limited "CDIL". He was employed with CDIL since 1987. Before joining CDIL he worked with Fleming GmbH as Research & Development Manager. Dr Walsh holds a PhD in Chemistry from University College Galway. - Jim Walsh，1995年10月第一次加入Trinity Biotech ，担任首席运营官。2007年，他辞去该职，成为本公司的非执行董事。2010年10月，他再次加入本公司，担任首席科学官。加入Trinity Biotech 之前，他是Cambridge Diagnostics Ireland Limited CDIL的总经理；他从1987年起任职于CDIL。加入CDIL之前，他是Fleming GmbH的研发经理。他在University College Galway获得化学博士学位。
- Jim Walsh initially joined Trinity Biotech in October 1995 as Chief Operations Officer. Dr Walsh resigned from the role of Chief Operations Officer in 2007 to become a Non Executive Director of the Company. In October, 2010 Dr Walsh rejoined the company as Chief Scientific Officer. Dr Walsh transferred from this position in 2015 and focuses on Business Development activities. Prior to joining Trinity Biotech, Dr Walsh was Managing Director of Cambridge Diagnostics Ireland Limited "CDIL". He was employed with CDIL since 1987. Before joining CDIL he worked with Fleming GmbH as Research & Development Manager. Dr Walsh holds a PhD in Chemistry from University College Galway.
- Denis R. Burger
-
Denis R. Burger自1992年6月起联合创始了Trinity Biotech，担任非执行董事，1992年6月至1995年5月曾任董事长。目前他是一家私人控股医药设备公司AMES Technology的董事长，也是在TSX上市的一家癌症治疗公司Lorus Therapeutics, Inc的非执行董事。直到2007年3月Burger先生都是在NASDAQ上市的一家生物技术公司AVI Biopharma Inc的董事长兼首席执行官。他也曾联合创始了Epitope Inc.，在1981年至1990年担任该公司的董事长。另外，Burger博士在波特兰的Oregon Health and Sciences University的微生物系、免疫系和肿瘤外科系担任教授，他于1965年获得伯克利的University of California的细菌学和免疫学学士学位，于1969年获得University of Arizona的微生物学和免疫学的硕博学位。
Denis R. Burger co-founded Trinity Biotech in June 1992 and acted as Chairman from June 1992 to May 1995. He is currently lead director of Aptose Biosciences, Inc, a cancer therapeutics, TSX and NASDAQ listed company. Until March 2007 Dr Burger was the Chairman and Chief Executive Officer of AVI Biopharma Inc, a NASDAQ listed biotechnology company. He was also a co-founder and, from 1981 to 1990 Chairman of Epitope Inc. In addition, Dr Burger has held a professorship in the Department of Microbiology and Immunology and Surgery Surgical Oncology at the Oregon Health and Sciences University in Portland. Dr Burger received his degree in Bacteriology and Immunology from the University of California in Berkeley in 1965 and his Master of Science and PhD in 1969 in Microbiology and Immunology from the University of Arizona. - Denis R. Burger自1992年6月起联合创始了Trinity Biotech，担任非执行董事，1992年6月至1995年5月曾任董事长。目前他是一家私人控股医药设备公司AMES Technology的董事长，也是在TSX上市的一家癌症治疗公司Lorus Therapeutics, Inc的非执行董事。直到2007年3月Burger先生都是在NASDAQ上市的一家生物技术公司AVI Biopharma Inc的董事长兼首席执行官。他也曾联合创始了Epitope Inc.，在1981年至1990年担任该公司的董事长。另外，Burger博士在波特兰的Oregon Health and Sciences University的微生物系、免疫系和肿瘤外科系担任教授，他于1965年获得伯克利的University of California的细菌学和免疫学学士学位，于1969年获得University of Arizona的微生物学和免疫学的硕博学位。
- Denis R. Burger co-founded Trinity Biotech in June 1992 and acted as Chairman from June 1992 to May 1995. He is currently lead director of Aptose Biosciences, Inc, a cancer therapeutics, TSX and NASDAQ listed company. Until March 2007 Dr Burger was the Chairman and Chief Executive Officer of AVI Biopharma Inc, a NASDAQ listed biotechnology company. He was also a co-founder and, from 1981 to 1990 Chairman of Epitope Inc. In addition, Dr Burger has held a professorship in the Department of Microbiology and Immunology and Surgery Surgical Oncology at the Oregon Health and Sciences University in Portland. Dr Burger received his degree in Bacteriology and Immunology from the University of California in Berkeley in 1965 and his Master of Science and PhD in 1969 in Microbiology and Immunology from the University of Arizona.
- Clint Severson
-
Clint Severson， 非执行董事，2008年11月作为非执行董事加入Trinity Biotech公司董事会。目前Severson先生担任Abaxis股份有限公司的董事长、总裁兼首席执行官，这是一家位于加州盟市，并且在纳斯达克（NASDAQ）上市的诊断公司。从1989年2月至1996年5月，Severson先生在MAST Immunosystems股份有限公司，一家私人控股的医疗诊断公司，担任总裁和首席执行官。迄今为止，他已经在医疗诊断行业累积了30年经验。
Clint Severson joined the board of Trinity Biotech in November 2008 as a non-executive director. Mr Severson served as Chairman and CEO of Abaxis Inc. from June, 1996 to August, 2018 a NASDAQ traded diagnostics company based in Union City, California. From February 1989 to May 1996 Mr Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company and to date he has accumulated over 40 years experience in the medical diagnostics industry. Mr Severson is also on the board of Cutera. - Clint Severson， 非执行董事，2008年11月作为非执行董事加入Trinity Biotech公司董事会。目前Severson先生担任Abaxis股份有限公司的董事长、总裁兼首席执行官，这是一家位于加州盟市，并且在纳斯达克（NASDAQ）上市的诊断公司。从1989年2月至1996年5月，Severson先生在MAST Immunosystems股份有限公司，一家私人控股的医疗诊断公司，担任总裁和首席执行官。迄今为止，他已经在医疗诊断行业累积了30年经验。
- Clint Severson joined the board of Trinity Biotech in November 2008 as a non-executive director. Mr Severson served as Chairman and CEO of Abaxis Inc. from June, 1996 to August, 2018 a NASDAQ traded diagnostics company based in Union City, California. From February 1989 to May 1996 Mr Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company and to date he has accumulated over 40 years experience in the medical diagnostics industry. Mr Severson is also on the board of Cutera.
- James D. Merselis
-
James D. Merselis，2009年2月至今，担任Trinity Biotech的非执行董事。他现为Biosensia Ltd的首席执行官，这是位于爱尔兰都柏林的即时检测诊断公司；也是Abram Scientific和Cardiac Designs的董事，前者位于加州的Mountain View，后者位于得克萨斯的Austin。他在医疗保健行业有着超过37年的工作经验，前22年任职于Boehringer Mannheim Diagnostics（现Roche Diagnostics）。他曾领导过一些医疗保健行业的初创企业。2002-2007，他担任HemoSense的总裁、首席执行官，这是一个即时检测诊断公司，为病人和医生提供快速检测结果，通过Warfarin或Coumadin的使用，以帮助控制中风风险。在此期间，他带领公司成功上市，纳斯达克代码：HEM；2年之后，它被Alere （纽交所代码： ALR）收购。他在以下初创企业担任过领导职务：Nexus Dx （现Samsung）、Alverix（现Becton Dickenson），和 Micronics（现 SONY）。
James D. Merselis joined the board of Trinity Biotech in February 2009. He is currently a Co-Founder and Managing Director of Synchrony Bio LLC, a newly formed healthcare-focused venture investment fund based in St. Louis, MO. He is also a non-executive director for the following companies: Kypha Inc., a St. Louis, Missouri based diagnostic company focused on Complement assays in the diagnosis and management of patients with inflammatory diseases; Geneoscopy, a St. Louis, Missouri based company developing next generation diagnostics that leverage the power of RNA to better prevent, detect, and treat gastrointestinal disease; and Abram Scientific Inc., a coagulation diagnostics company located in Palo Alto, California. Mr. Merselis has more than forty years experience in healthcare, including twenty-two years at Boehringer Mannheim Diagnostics now Roche Diagnostics. Mr. Merselis has led a number of healthcare diagnostic start-ups. From 2002 to 2007 he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of Warfarin or Coumadin. During this time he successfully took the company public (AMEX:HEM) followed two years later by its acquisition by Alere (now Abbott) (NYSE:ABT). His leadership at other start-ups has included: Nexus Dx (now Samsung), Alverix, Inc. (now Becton Dickenson), and Micronics, Inc. (now SONY). - James D. Merselis，2009年2月至今，担任Trinity Biotech的非执行董事。他现为Biosensia Ltd的首席执行官，这是位于爱尔兰都柏林的即时检测诊断公司；也是Abram Scientific和Cardiac Designs的董事，前者位于加州的Mountain View，后者位于得克萨斯的Austin。他在医疗保健行业有着超过37年的工作经验，前22年任职于Boehringer Mannheim Diagnostics（现Roche Diagnostics）。他曾领导过一些医疗保健行业的初创企业。2002-2007，他担任HemoSense的总裁、首席执行官，这是一个即时检测诊断公司，为病人和医生提供快速检测结果，通过Warfarin或Coumadin的使用，以帮助控制中风风险。在此期间，他带领公司成功上市，纳斯达克代码：HEM；2年之后，它被Alere （纽交所代码： ALR）收购。他在以下初创企业担任过领导职务：Nexus Dx （现Samsung）、Alverix（现Becton Dickenson），和 Micronics（现 SONY）。
- James D. Merselis joined the board of Trinity Biotech in February 2009. He is currently a Co-Founder and Managing Director of Synchrony Bio LLC, a newly formed healthcare-focused venture investment fund based in St. Louis, MO. He is also a non-executive director for the following companies: Kypha Inc., a St. Louis, Missouri based diagnostic company focused on Complement assays in the diagnosis and management of patients with inflammatory diseases; Geneoscopy, a St. Louis, Missouri based company developing next generation diagnostics that leverage the power of RNA to better prevent, detect, and treat gastrointestinal disease; and Abram Scientific Inc., a coagulation diagnostics company located in Palo Alto, California. Mr. Merselis has more than forty years experience in healthcare, including twenty-two years at Boehringer Mannheim Diagnostics now Roche Diagnostics. Mr. Merselis has led a number of healthcare diagnostic start-ups. From 2002 to 2007 he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of Warfarin or Coumadin. During this time he successfully took the company public (AMEX:HEM) followed two years later by its acquisition by Alere (now Abbott) (NYSE:ABT). His leadership at other start-ups has included: Nexus Dx (now Samsung), Alverix, Inc. (now Becton Dickenson), and Micronics, Inc. (now SONY).
- Kevin Tansley
-
Kevin Tansley，首席财务官；2003年3月加入Trinity Biotech；2007年11月，被任命为首席财务官、董事会秘书。他曾是Arthur Andersen & Co企业财务服务业务的特许会计师，有着丰富的经验。2003年加入Trinity Biotech之前，他在Irish electricity utility ESB担任过一些财务职位。他在University College Dublin 获得会计硕士学位，是爱尔兰Institute of Chartered Accountants的资深会员。
Kevin Tansley joined Trinity Biotech in March 2003 and was appointed Chief Financial Officer and Secretary to the Board of Directors in November 2007. Mr. Tansley was appointed to the board in September 2016 as Executive Director. Mr Tansley trained as a chartered accountant in the Corporate Financial Services practice of Arthur Andersen & Co. Prior to joining Trinity Biotech in 2003 Mr Tansley held a number of financial positions in the Irish electricity utility ESB. Mr Tansley holds a Masters of Accounting from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. - Kevin Tansley，首席财务官；2003年3月加入Trinity Biotech；2007年11月，被任命为首席财务官、董事会秘书。他曾是Arthur Andersen & Co企业财务服务业务的特许会计师，有着丰富的经验。2003年加入Trinity Biotech之前，他在Irish electricity utility ESB担任过一些财务职位。他在University College Dublin 获得会计硕士学位，是爱尔兰Institute of Chartered Accountants的资深会员。
- Kevin Tansley joined Trinity Biotech in March 2003 and was appointed Chief Financial Officer and Secretary to the Board of Directors in November 2007. Mr. Tansley was appointed to the board in September 2016 as Executive Director. Mr Tansley trained as a chartered accountant in the Corporate Financial Services practice of Arthur Andersen & Co. Prior to joining Trinity Biotech in 2003 Mr Tansley held a number of financial positions in the Irish electricity utility ESB. Mr Tansley holds a Masters of Accounting from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.
高管简历
中英对照 | 中文 | 英文- Ronan O'Caoimh
Ronan O'Caoimh，董事长、首席执行官；在1992年6月参与创办Trinity Biotech，并担任首席财务官，直到1994年3月，他成为首席执行官。1995年5月，他还当选为董事长。2007年11月，本公司首席执行官和董事长的职务分离，他于是担任执行董事长。2008年10月，公司首席执行官辞职，他重新担任首席执行官、董事长。加入Trinity Biotech之前，他是爱尔兰诊断公司Noctech Limited的总经理；1988年起，担任其财务总监，直到至1991年1月成为总经理。他在University College Dublin获得商业学士学位，是爱尔兰Institute of Chartered Accountants的资深会员。2011年3月30日，他担任本公司首席执行官的服务协议终止，取而代之的是与Darnick Limited的服务协议。
Ronan O'Caoimh, Chairman and Chief Executive Officer, co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. In November 2007 it was decided to separate the role of Chief Executive Officer and Chairman and Mr O'Caoimh assumed the role of Executive Chairman. In October 2008 following the resignation of the Chief Executive Officer, Mr. O'Caoimh resumed the role of Chief Executive Officer and Chairman. Prior to joining Trinity Biotech, Mr O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O'Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O'Caoimh holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. On March 30 2011 the service agreement with Ronan O'Caoimh as Chief Executive Officer was terminated and replaced by an agreement with Darnick Limited.- Ronan O'Caoimh，董事长、首席执行官；在1992年6月参与创办Trinity Biotech，并担任首席财务官，直到1994年3月，他成为首席执行官。1995年5月，他还当选为董事长。2007年11月，本公司首席执行官和董事长的职务分离，他于是担任执行董事长。2008年10月，公司首席执行官辞职，他重新担任首席执行官、董事长。加入Trinity Biotech之前，他是爱尔兰诊断公司Noctech Limited的总经理；1988年起，担任其财务总监，直到至1991年1月成为总经理。他在University College Dublin获得商业学士学位，是爱尔兰Institute of Chartered Accountants的资深会员。2011年3月30日，他担任本公司首席执行官的服务协议终止，取而代之的是与Darnick Limited的服务协议。
- Ronan O'Caoimh, Chairman and Chief Executive Officer, co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. In November 2007 it was decided to separate the role of Chief Executive Officer and Chairman and Mr O'Caoimh assumed the role of Executive Chairman. In October 2008 following the resignation of the Chief Executive Officer, Mr. O'Caoimh resumed the role of Chief Executive Officer and Chairman. Prior to joining Trinity Biotech, Mr O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O'Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O'Caoimh holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. On March 30 2011 the service agreement with Ronan O'Caoimh as Chief Executive Officer was terminated and replaced by an agreement with Darnick Limited.
- Kevin Tansley
Kevin Tansley，首席财务官；2003年3月加入Trinity Biotech；2007年11月，被任命为首席财务官、董事会秘书。他曾是Arthur Andersen & Co企业财务服务业务的特许会计师，有着丰富的经验。2003年加入Trinity Biotech之前，他在Irish electricity utility ESB担任过一些财务职位。他在University College Dublin 获得会计硕士学位，是爱尔兰Institute of Chartered Accountants的资深会员。
Kevin Tansley joined Trinity Biotech in March 2003 and was appointed Chief Financial Officer and Secretary to the Board of Directors in November 2007. Mr. Tansley was appointed to the board in September 2016 as Executive Director. Mr Tansley trained as a chartered accountant in the Corporate Financial Services practice of Arthur Andersen & Co. Prior to joining Trinity Biotech in 2003 Mr Tansley held a number of financial positions in the Irish electricity utility ESB. Mr Tansley holds a Masters of Accounting from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.- Kevin Tansley，首席财务官；2003年3月加入Trinity Biotech；2007年11月，被任命为首席财务官、董事会秘书。他曾是Arthur Andersen & Co企业财务服务业务的特许会计师，有着丰富的经验。2003年加入Trinity Biotech之前，他在Irish electricity utility ESB担任过一些财务职位。他在University College Dublin 获得会计硕士学位，是爱尔兰Institute of Chartered Accountants的资深会员。
- Kevin Tansley joined Trinity Biotech in March 2003 and was appointed Chief Financial Officer and Secretary to the Board of Directors in November 2007. Mr. Tansley was appointed to the board in September 2016 as Executive Director. Mr Tansley trained as a chartered accountant in the Corporate Financial Services practice of Arthur Andersen & Co. Prior to joining Trinity Biotech in 2003 Mr Tansley held a number of financial positions in the Irish electricity utility ESB. Mr Tansley holds a Masters of Accounting from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.